<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844334</url>
  </required_header>
  <id_info>
    <org_study_id>CIP EMEA 18-02</org_study_id>
    <nct_id>NCT03844334</nct_id>
  </id_info>
  <brief_title>CLinical EValuation of WEB 0.017 Device in Intracranial AneuRysms</brief_title>
  <acronym>CLEVER</acronym>
  <official_title>CLEVER: CLinical EValuation of WEB 0.017 Device in Intracranial AneuRysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microvention-Terumo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Microvention-Terumo, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an observational, European, multi-center, prospective assessment of the clinical
      utility of the 0.017 WEB Aneurysm Embolization System in subjects with intracranial aneurysms
      deemed appropriate for endovascular treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible subjects presenting to the participating Centers will be considered for entry
      into the study. Up to 160 evaluable subjects meeting the study entry criteria will be
      enrolled.

      Subjects will be followed per Institution's standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Aneurysm occlusion</measure>
    <time_frame>12 months</time_frame>
    <description>Angiographic (conventional Angio) occlusion based on Raymond-Roy occlusion scale The Raymond-Roy occlusion classification (RROC) is an angiographic classification scheme for grading the occlusion of endovascularly treated intracranial aneurysms.
class I: complete obliteration
class II: residual neck
class III: residual aneurysm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of major stroke or neurological deaths</measure>
    <time_frame>12months</time_frame>
    <description>The proportion of subjects with death of any nonaccidental cause or any major stroke within the first 30 days after treatment or major ipsilateral stroke or death due to neurologic cause from day 31 to the 1 year after treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Brain Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WEB Aneurysm Embolization System</intervention_name>
    <description>Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured or unruptured intracranial aneurysms.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The decision to use a WEB device to treat the patient has been made before and
        independently of the decision to include the patient in this study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be ≥ 18 years of age and ≤80 years of age

          2. Subject must have an intracranial aneurysm (IA),

          3. Subject must sign and date Ethics Committee approved written informed consent prior to
             initiation of any clinical interventional procedures or when applicable, register the
             patient non opposition to the study data collection

          4. For ruptured aneurysm, Subject with Hunt &amp; Hess Score ≤ III

        Exclusion Criteria:

          1. Subject has an IA with characteristics unsuitable for endovascular treatment

          2. Subject's index IA was previously treated

          3. Subject has stroke-in-evolution within the prior 30 days

          4. An additional aneurysm must be treated during the procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Habib NACER-CHERIF</last_name>
    <phone>+33 (0)6 81 97 46 24</phone>
    <email>habib.nacercherif@microvention.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia BOYER</last_name>
    <phone>+33 (0)6 70 13 94 98</phone>
    <email>patricia.boyer@microvention.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Spelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christophe Cognard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Fischer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Clinical Neurosciences</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>István Szikora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

